Equities

Alpa Laboratories Ltd

Alpa Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)112.97
  • Today's Change-2.68 / -2.32%
  • Shares traded125.74k
  • 1 Year change+57.34%
  • Beta1.0216
Data delayed at least 15 minutes, as of Sep 20 2024 11:29 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments947844765
Total Receivables, Net511507388
Total Inventory148137155
Prepaid expenses3.122.53--
Other current assets, total0.670.0082
Total current assets1,6101,4911,389
Property, plant & equipment, net1147092
Goodwill, net----1.04
Intangibles, net0.600.83--
Long term investments837870
Note receivable - long term1119--
Other long term assets5.20140.00
Total assets1,8241,6731,552
LIABILITIES
Accounts payable118151149
Accrued expenses1112--
Notes payable/short-term debt45023
Current portion long-term debt/capital leases7.881514
Other current liabilities, total99118127
Total current liabilities281296314
Total long term debt07.7721
Total debt522358
Deferred income tax2423--
Minority interest------
Other liabilities, total0.000.000.00
Total liabilities305327335
SHAREHOLDERS EQUITY
Common stock210210210
Additional paid-in capital550550--
Retained earnings (accumulated deficit)7595861,007
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity1,5191,3461,217
Total liabilities & shareholders' equity1,8241,6731,552
Total common shares outstanding212121
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.